Mereo BioPharma 5

Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases and oncology. The company's strategy involves acquiring and advancing mid-to-late-stage clinical assets that have been deprioritized by large pharmaceutical companies. Its lead program, setrusumab, is being developed in collaboration with Ultragenyx for the treatment of osteogenesis imperfecta and is currently in Phase 3 clinical trials. Mereo's diverse pipeline also includes etigilimab, an anti-TIGIT antibody for solid tumors, and alvelestat, a neutrophil elastase inhibitor for respiratory diseases.